Soren Carlsen, MD
Urology · Wailuku, HINPI 1063568657
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,131 of the $6,486 with a category attached, or 63.7%. 25 manufacturers reported payments, led by Medtronic at 24.9% of the total. 2025 is the largest year on record at $2,571, more than ten times the $223 reported in 2019.
Across 179 payments — averaging $36.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Astellas Pharma US Inc$1K
- Pfizer$597
- Neotract Inc.$561
- AbbVie$478
- Teleflex LLC$411
- plus $2K from 19 others
What the payments were for
- Travel & lodging$1,75027%
- Food & beverage$4,13164%
- Education$6069%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 5 | $1,612 |
| Astellas Pharma US Inc | 30 | $1,154 |
| Pfizer | 21 | $597 |
| Neotract Inc. | 8 | $561 |
| AbbVie(2 entities) | 26 | $478 |
| Teleflex LLC | 15 | $411 |
| Johnson & Johnson(2 entities) | 13 | $347 |
| Boston Scientific | 9 | $190 |
| Bluewind Medical | 1 | $141 |
| Rochester Medical Corporation | 8 | $132 |
| Myovant Sciences Inc. | 7 | $122 |
| Endo Pharmaceuticals Inc. | 6 | $118 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $112 |
| Merck | 4 | $83 |
| Urogen Pharma, Inc. | 3 | $78 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Bayer | 3 | $61 |
| Axonics, Inc. | 2 | $46 |
| Sumitomo Pharma America, Inc. | 3 | $45 |
| Angiodynamics, Inc. | 1 | $26 |
| Endo USA, Inc. | 1 | $24 |
| ABC Home Medical Supply, Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| Ambu Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,486 in reported general payments places this provider in the 80th percentile of 46 urology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 64 | $819,687 |
| MyrbetriqMirabegron | 114 | $120,762 |
| Tamsulosin Hcl | 686 | $14,108 |
| Finasteride | 450 | $8,709 |
| Tolterodine Tartrate ErTolterodine Tartrate | 38 | $6,977 |
| Solifenacin Succinate | 138 | $6,325 |
| Dutasteride | 100 | $4,957 |
| Methenamine Hippurate | 51 | $4,793 |
| Trospium Chloride ErTrospium Chloride | 19 | $4,435 |
| Potassium Citrate ErPotassium Citrate | 35 | $3,853 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 144 | $3,551 |
| Desmopressin Acetate | 27 | $3,224 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 23 | $3,082 |
| Estradiol | 41 | $2,447 |
| Tadalafil | 16 | $2,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,154 | $940,450178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 46 urology providers in Hawaii.
Other urology in Wailuku
- Alicia RostonWailuku$4K
- Todd HoekstraWailuku$0
- Benjamin ShurtleffWailuku$0
- Sergei TikhonenkovHonolulu$22K
- Timur RoytmanHonolulu$22K
- Franklin LeeAiea$12K
- Robert CarlileHonolulu$10K
- Charles KimHonolulu$9K
- David WeiHonolulu$9K
- Andrew SunHonolulu$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.